OTCMKTS:SPHRY - STARPHARMA HOLD/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.79 -0.24 (-2.66 %) (As of 05/23/2019 03:22 PM ET)Previous Close$9.03Today's Range$8.79 - $8.8052-Week Range$6.61 - $11.87Volume326 shsAverage Volume288 shsMarket Capitalization$326.64 millionP/E RatioN/ADividend YieldN/ABeta1.39 ProfileAnalyst RatingsChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia. Receive SPHRY News and Ratings via Email Sign-up to receive the latest news and ratings for SPHRY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SPHRY Previous Symbol CUSIPN/A CIKN/A Webhttp://www.starpharma.com/ Phone61-3-8532-2700Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.79 million Price / Sales86.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.11 per share Price / Book7.92Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares37,160,000Market Cap$326.64 million Next Earnings DateN/A OptionableNot Optionable STARPHARMA HOLD/S (OTCMKTS:SPHRY) Frequently Asked Questions What is STARPHARMA HOLD/S's stock symbol? STARPHARMA HOLD/S trades on the OTCMKTS under the ticker symbol "SPHRY." What is the consensus analysts' recommendation for STARPHARMA HOLD/S? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STARPHARMA HOLD/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STARPHARMA HOLD/S. Has STARPHARMA HOLD/S been receiving favorable news coverage? News coverage about SPHRY stock has been trending somewhat positive on Thursday, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. STARPHARMA HOLD/S earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the stock's share price in the near term. Who are some of STARPHARMA HOLD/S's key competitors? Some companies that are related to STARPHARMA HOLD/S include Intrexon (XON), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Anavex Life Sciences (AVXL), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Senomyx (SNMX), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), Vitality Biopharma (VBIO), Tenax Therapeutics (TENX) and US Stem Cell (USRM). What other stocks do shareholders of STARPHARMA HOLD/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other STARPHARMA HOLD/S investors own include Starpharma (SPL) and AstraZeneca (AZN). Who are STARPHARMA HOLD/S's key executives? STARPHARMA HOLD/S's management team includes the folowing people: Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 56)Mr. Nigel J. Baade, CFO & Company Sec.Dr. A. Eglezos BSc(Hons), Ph.D., MBA, VP of Bus. Devel.Dr. Jeremy R. Paull BSc (Hons), Ph.D., VP of Devel. & Regulatory AffairsDr. David J. Owen BSc(Hons) Ph.D., VP of Research How do I buy shares of STARPHARMA HOLD/S? Shares of SPHRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is STARPHARMA HOLD/S's stock price today? One share of SPHRY stock can currently be purchased for approximately $8.79. How big of a company is STARPHARMA HOLD/S? STARPHARMA HOLD/S has a market capitalization of $326.64 million and generates $3.79 million in revenue each year. What is STARPHARMA HOLD/S's official website? The official website for STARPHARMA HOLD/S is http://www.starpharma.com/. How can I contact STARPHARMA HOLD/S? STARPHARMA HOLD/S's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company can be reached via phone at 61-3-8532-2700 or via email at [email protected] MarketBeat Community Rating for STARPHARMA HOLD/S (OTCMKTS SPHRY)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 10 (Vote Outperform)Underperform Votes: 12 (Vote Underperform)Total Votes: 22MarketBeat's community ratings are surveys of what our community members think about STARPHARMA HOLD/S and other stocks. Vote "Outperform" if you believe SPHRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Diluted Earnings Per Share Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.